Torasemide in hypertension and heart failure: re-inventing loop diuretic therapy?
Torasemide in hypertension and heart failure: re-inventing loop diuretic therapy?
复制标题
DOI：
10.2174/1381612827666210406142933
复制
发表时间：
2021-04
影响因子：
3.1
通讯作者：
A. Manolis;M. Kallistratos;M. Doumas
中科院分区：
文献类型：
--
作者：
A. Manolis;M. Kallistratos;M. Doumas
在心力衰竭(HF)患者中，目前的欧洲心脏病学会(ESC)指南建议使用三种环状利尿剂(速尿、托拉塞米、布美塔尼)，以减少心力衰竭住院时间，并改善有充血症状和/或症状的患者的症状和运动能力。此外，欧洲高血压学会(ESH)指南首次建议高血压患者使用托拉塞米。本文综述了环状利尿剂的作用方式，介绍了它们的药代动力学特征，并讨论了它们在治疗动脉高血压和心力衰竭中的地位，但重点是托拉塞米。
In heart failure (HF) patients, current European Society of Cardiology (ESC) guidelines recommends the use of three loop diuretics (furosemide, torasemide, bumetanide) in order to reduce HF hospitalizations but also to improve symptoms and exercise capacity in patients with signs and/or symptoms of congestion. In addition, for the first time in hypertensive patients, European Society of Hypertension (ESH) guidelines recommend the use of torasemide. This review aimed to summarize the mode of action of loop diuretics, to present their pharmacokinetic characteristics, and to discuss their place in the management of arterial hypertension and heart failure, with special emphasis however on torasemide.